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Human papillomavirus (HPV) vaccines are safe and effective in preventing HPV infection
and cervical precancers. Neutralizing antibodies are thought to be the primary mechanism
of protection for HPV vaccines, although the exact level required for protection has not
been identified. Three common serological assays used in clinical trials to measure HPV
antibodies are HPV pseudovirion-based neutralization assay (PBNA), competitive or total
Luminex immunoassays (cLIA or LIA) and VLP-based enzyme linked immunosorbent
assays (ELISA). While PBNA is the gold-standard for measuring neutralizing antibodies
(NAb), it is labor intensive. Luminex immunoassay and VLP-ELISA are rapid and high
throughput, but their reagents and equipment can be difficult to source. Nevertheless,
data generated from these assays generally correlate well with PBNA. Here, we described
a simplified high-throughput PsV-based ELISA for HPV antibody measurement, to
circumvent some of the limitations of existing assays. Using this assay, we were able to
differentiate HPV-specific IgG and IgM, and found a strong correlation between HPV-
specific IgG and NAb levels, as previously determined by PBNA. This assay platform is
simpler and less time-consuming than PBNA. In addition, the materials can be readily
produced and obtained commercially. This assay can be used as an alternative method to
measure HPV antibodies.
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Toh et al. HPV Pseudovirion-Based ELISAINTRODUCTION
Three licensed virus-like particle (VLP)-based human
papillomavirus (HPV) vaccines (Gardasil, Cervarix, Gardasil9) are
highly immunogenic, safe and effective in preventing vaccine-type
HPV infections and cervical cancer precursors (1). These
prophylactic vaccines are given as three-dose schedules to
individuals aged 15 to 26 years. A two-dose schedule separated by
6 months is recommended to those aged 9 to 14 years based on
noninferiority studies. However, for immunosuppressed
individuals, the recommendation is to receive three doses of the
HPV vaccine (2). Recent observational data suggests that one dose
of HPV vaccine is immunogenic and can produce antibodies that
persist for at least 7 years andmay be protective against vaccine-type
HPV infection and HPV-related diseases (3–5). The results of
ongoing randomized clinical trials of single dose HPV schedules
are greatly anticipated (3).
Neutralizing antibodies (NAb) are thought to be the primary
mechanism of protection for HPV vaccines, although the exact
level required for protection has not been defined as there have
been no breakthrough cases identified to date. Three serological
assays are commonly used in clinical trials to measure HPV
antibodies. They are HPV pseudovirion-based neutralization
assay (PBNA), competitive or total Luminex immunoassays
(cLIA or LIA) and VLP-based enzyme linked immunosorbent
assays (ELISA) (6). The PBNA are considered the “gold
standard” for assessing protective total neutralizing antibodies
induced by the vaccines. It is a chemiluminescent-based assay
utilizing HPV pseudovirions (PsV) (self-assembled HPV L1 or
L1-L2 proteins and a reporter gene produced through molecularFrontiers in Immunology | www.frontiersin.org 2biology technology) and human embryonic kidney cell line
(HEK293TT/293FT cells), as described previously (7). cLIA or
LIA is a multiplex-bead based assay that measures neutralizing
monoclonal antibodies that compete with an individual’s serum
antibodies for binding to a specific immunodominant epitope or
whole HPV VLPs epitopes, respectively (8, 9). Although cLIA is
highly specific, it only measures NAbs competing for one
epitope, which means that only a subset of total NAb are
detected. In contrast, VLP-based ELISAs measures all
neutralizing and non-neutralizing antibodies, which may
overestimate the antibody response. Nevertheless, all three
assays generally correlate well, particularly in specimens with
high antibody levels (6).
While PBNA is the gold-standard, the assay is difficult to set
up and laborious. Furthermore, PBNA does not discriminate
between different antibody isotypes and subclasses. cLIA/LIA
and VLP-ELISA are rapid and high throughput, but the reagents
and equipment are difficult to source. To establish a simpler and
easier method of measuring HPV-specific antibodies, as well as
the potential to measure different antibody characteristics (i.e.,
different isotypes and subclasses), we established an HPV PsV-
based ELISA to measure HPV-specific IgG and IgM antibody
responses. In this report, we provide detailed protocols for the
production of HPV pseudovirions (Part I), as well as for setting
up the ELISA that we have developed (Part II) (Figure 1). We
believe that this protocol will be useful for laboratories that are
examining or planning to set up HPV serology capacity. The
described protocol setup works well for us, but it can easily be
modified and adapted to each laboratory needs and improved by
the research community in the future.FIGURE 1 | Protocol overview.October 2020 | Volume 11 | Article 585768
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METHODS
The reagents/materials and the equipments to conduct this assay
are listed in Tables 1 and 2, respectively.
Maintenance of HEK293TT Cells
The HEK293TT cells (human embryonic kidney cell line) were
kindly provided by Prof Ian Frazer’s laboratory (The University
of Queensland Diamantina Institute, Australia) under a
Materials Transfer Agreement. A cryovial of HEK293TT cells
was thawed by adding DMEM media consisting of 20% heat-
inactivated FBS, 1% minimum NEAA, 1% Glutamax and 1%
PSG slowly in dropwise motion and transferred into a 50-ml
conical centrifuge tube. Approximately 20 ml of media was
slowly added with constant flicking of tube to ensure proper
mixing and then transferred into a 75cm2 tissue culture flask
(T75). The cells were incubated at 37°C, 5% CO2 for 2 to 3 daysFrontiers in Immunology | www.frontiersin.org 3before cell passage. Following thawing of HEK293TT cells, they
were passaged at least twice before use in PsV production.
Cells were passaged twice weekly at 70% to 80% confluence. Cell
passage began with removal of culture medium, followed by
washing of cells twice with 5 ml of PBS. Trypsin (0.25%) was
then added to detach cells from the flask surface and incubated at
37°C for 1 to 2 min. The cells were then resuspended in 9 ml of D10
media (DMEMmedium consisting of 10% heat-inactivated FBS, 1%
minimum NEAA, 1% Glutamax and 1% PSG) and split at a 1:6 or
1:12 ratio into a T75 flask depending on level of cell confluence.
Production of HPV Pseudovirions (PsV)
HPV Plasmid Extraction and Validation
The HPV plasmid DNA was obtained from Addgene
(Cambridge, USA) in Escherichia coli stab. The bacteria
containing HPV plasmid 16 were cultured on Luria-Bertani
(LB) agar plates and broth containing specific antibiotics.
HPV16 plasmid DNA was extracted from the bacteria using
Qiagen Maxiprep kit according to manufacturer’s instructionTABLE 1 | Reagents/Materials.
Purpose Name Manufacturer Location
Plasmid extraction and validation HPV plasmids Addgene Cambridge, USA
Qiagen Maxiprep kit Qiagen Hilden, Germany
Luria-Bertani (LB) media Oxoid VIC, Australia
Agarose Oxoid VIC, Australia
*Antibiotics Sigma-Aldrich MO, USA
*Restriction enzymes
Production of HPV pseudovirions HEK293TT or FT cells Thermofisher Scientific VIC, Australia
Dulbecco’s Modified Eagle’s Medium (DMEM) Gibco Life Technologies NY, USA
Fetal Bovine Serum (FBS) Hyclone GE Healthcare Life Sciences UT, USA
Minimum Non-Essential Amino Acid (Minimum NEAA) Gibco Life Technologies NY, USA
Glutamax Gibco Life Technologies NY, USA
Penicillin-Streptomycin-Glutamine (PSG) Gibco Life Technologies NY, USA
Phosphate-Buffered Saline (PBS) Gibco Life Technologies NY, USA
Trypsin Gibco Life Technologies NY, USA
Lipofectamine Invitrogen CA, USA
Opti-MEM® Gibco Life Technologies NY, USA
RNAse cocktail Ambion CA, USA
Brij Sigma-Aldrich MO, USA
50-ml centrifuge tube Corning Incorporated NY, USA
T75 Flask Corning Incorporated NY, USA
Protein quantification BCA protein assay
(Cat no.: 23227)
Thermofisher Scientific VIC, Australia
ELISA Maxisorp 96-well plates Thermofisher Scientific VIC, Australia
PBS-0.05%Tween Sigma-Aldrich MO, USA
Mouse anti-human IgG or IgM monoclonal antibodies Southern Biotech AL, USA
3,3′,5,5′-tetramethylbenzidine KPL MA, USA
1M Phosphoric Acid Merck VIC, AustraliaOctober 2020 | Volume 11*Antibiotics and restriction enzymes are specific for each HPV type.TABLE 2 | Equipment.
Name Manufacturer Location
Nanodrop 2000 spectrophotometer Thermo Scientific VIC, Australia
ELISA Plate Reader BioTek Instruments VT, USA
Centrifuge LAF Technologies VIC, Australia
Ultra-centrifuge Beckman Coulter IN, USA
Biosafety Cabinet Sigma-Aldrich Munich, Germany| Article 585768
Toh et al. HPV Pseudovirion-Based ELISAand quantified using Nanodrop 2000 spectrophotometer.
HPV16 plasmid DNA was then validated via restriction
enzyme digestion and agarose gel electrophoresis.
Transfection of HEK293TT Cells
Production of HPV PsV was done by transfecting HEK293TT
cells with HPV16 plasmid DNA. Three days prior to
transfection, the cells were prepared at a concentration of 2 x
106 per 15 ml of media in T75 flask and were incubated for 3 days
at 37°C and 5% CO2. At day 3, a mastermix of 85 mL of
lipofectamine and 2 ml of Opti-MEM®, as well as 19ug of
HPV16 plasmid DNA in 2 mL of Opti-MEM® were prepared
for each flask and incubated at room temperature (RT) for
20 min. The plasmid DNA-Opti-MEM® mixture and
mastermix were then combined and incubated for a further
20 min. The mixture was then added to the flask that was
prepared 3 days prior and incubated at 37°C, 5% CO2 for 5 h.
Following incubation, media containing DNA-mastermix
mixture was replaced with 15 ml of D10 media, and cells were
incubated for 48 h at 37°C, 5% CO2.
After 48 h, cell supernatants were collected into a 50-ml tube
and 2 ml of 0.25% trypsin was added to the flask followed by
incubation for 2 min at 37°C, 5% CO2 to detach the transfected
cells from the flask. To neutralise the action of trypsin and
resuspend cells, 5 ml of collected cell supernatant was added to
flask and the cells were then collected in 15 ml tube. The flask
was rinsed with 3 ml PBS to collect as many cells as possible.
Cells were then spun via centrifugation at 1200 rpm and 4°C for
5 min. Following that, the cells were resuspended in 10 ml PBS
and centrifuged again at 1200 rpm and 4°C for 5 min. Finally,
cells were resuspended in 1 ml of PBS containing 9.5 mM
magnesium (PBS-Mg). Following resuspension, cells were
transferred to a low-binding microfuge tube and PBS-Mg
added at 1.5 times the total cell volume. RNAse cocktail and
10% Brij were also added at 1:1,000 and 1:25 of the total cell
volume, respectively. The cell lysates containing the PsV were
then incubated at 37°C, 5% CO2 overnight for maturation. The
PsVs were then aliquoted, snap-frozen, and stored at −80°C until use.
PsV-ELISA
The amount of PsV proteins were determined by BCA protein
assay prior to use for ELISA. 96-well high protein-binding ELISA
plates were coated with 25 µg/ml of HPV16 PsV in PBS and
incubated overnight at 4°C. Plates were washed with PBS-0.05%
Tween and then blocked for 1 h with 10% FCS/PBS at 37°C.
Samples (1:100) were serially diluted in 10% FCS/PBS and added
to the plate along with negative (10% FCS/PBS) and positive
(sera from vaccinated individuals) controls and incubated for 2 h
at 37°C. A standard made up of pooled sera from vaccinated
individuals were serially diluted and were used to determine the
sample concentration (a value of 10 ELISA units (EU)/ml was
assigned to the top standard). Plates were washed with PBS-
0.05%Tween three times and goat anti-human IgG-HRP
(1:2500) or goat anti-human IgM-HRP (1:2500) was added.
Plates were incubated for 2 h at 37°C. After another three
washes with PBS-0.05%Tween, substrate solution was added
for 9mins before stopping the reaction with 1M phosphoricFrontiers in Immunology | www.frontiersin.org 4acid. Plates were read on a microplate reader at 450nm with a
reference wavelength of 630 nm.
Study Samples
The clinical samples used were derived from a cohort study in Fiji,
which has been described in detail previously (5). Briefly, 200 Fijian
girls (15–19 years old) who were previously unimmunized, or
immunized with one to three doses of 4vHPV (Gardasil®, Merck
Inc.) six years earlier were recruited. A booster dose of 2vHPV
(Cervarix®, GSK) was given to all girls. Blood was taken pre- and 28
days following 2vHPV. A subset of samples [3-dose group (N=16),
2-dose group (N=16), 1-dose group (N=18), 0-dose group (N=20)]
from each 4vHPV dosage groups were used for this analysis. All
samples were randomized and tested in a blinded manner.
Statistical Analysis
Unpaired t-tests were used to compare the geometric mean of
IgG/IgM levels (with 95% CIs) between girls who were
unimmunized or were immunized with one to three doses of
4vHPV pre- and 28-days following 2vHPV. A nonparametric
Spearman’s correlation was performed between NAb titers
previously determined (5) and IgG or IgM` EU/ml. The
agreement between PBNA and PsV-ELISA was calculated
using the number of double-positive results plus the number of
double-negative results divided by the total number of samples
analyzed. All statistical analyses were performed using Graphpad
Prism 7.0. A p-value < 0.05 was considered significant.RESULTS
Optimization of PsV-ELISA
We tested three different antigen coating concentrations (50, 25,
and 5 µg/ml) and two secondary antibody concentrations
(1:2500 and 1:5000). We found that a coating concentration of
25 µg/ml and 1:2500 gave us the highest readout with the least
background (Supplementary Figure 1).
Assay Testing Using Serum From
Vaccinated and Unvaccinated Individuals
To verify our assay, we measured HPV16-specific IgG and IgM
antibody responses using serum samples collected from a cohort
study in Fiji; girls previously immunized with one to three doses
of 4vHPV six years before (pre), and one month after a dose of
2vHPV (post).
Six years after the last dose of 4vHPV, we detected a dose
response between the different 4vHPV dosage groups, with higher
IgG levels in higher dosage groups. Significantly higher IgG levels
were found in girls who were previously immunized with one to
three doses of 4vHPV when compared with unimmunized girls
(Figure 2A). Statistically higher IgM levels were in unimmunized
girls compared with girls previously immunized with three doses of
4vHPV (Figure 2B).
Following a dose of 2vHPV, a statistically significant increase in
IgG levels were detected in all dosage groups (p<0.0001 in all cases)
(Figure 3A). Girls previously immunized with one to three doses ofOctober 2020 | Volume 11 | Article 585768
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(p<0.0001 in all cases). Within dosage groups, girls previously
immunized with three and two doses of 4vHPV had a 17- and
18-fold increase in IgG levels, respectively, and girls previously
immunized with one dose of 4vHPV had a 79-fold increase, whilst
the previously unimmunized girls had a 5-fold increase in IgG. Only
girls previously unimmunized had significantly higher IgM levels
(2-fold) following a dose of 2vHPV (Figure 3B); their level was
significantly higher than girls previously immunized with three
(p<0.001), two (p=0.03) and one dose (p=0.011) of 4vHPV.
We also examined antibodies to HPV18 on a subset of
samples (N=26) using this assay, and similar observations as
HPV16 antibody responses were found between different dosage
groups (Supplementary Figure 2).Frontiers in Immunology | www.frontiersin.org 5Correlation and Agreement Between PsV-
ELISA and PBNA
To validate our data, we correlated NAb titers (effective dose 50,
ED50) previously determined by PBNA in our laboratory, with
the values produced by PsV-ELISA. A strong statistically
significant (p<0.0001) positive correlation were found between
IgG levels (PsV-ELISA) and NAb titers (PBNA) (Figure 4A),
while no correlation between IgM and NAb titers were found
(Figure 4B). When stratified by dosage groups, strong
statistically significant (p<0.0001) positive correlations were
found between the IgG and NAb titers for all dosage groups
(Figure 5), whereas only girls in the 0-dose group had a
moderately significant positive correlation between the IgM
and NAb titers (Figure 6).A B
FIGURE 3 | HPV16-specific antibody responses measured by PsV-ELISA pre- and post-2vHPV. (A) HPV-specific IgG levels (B) HPV-specific IgM levels. Each dot
represents an individual sample; error bars represent geometric mean ± 95% confidence interval. **p < 0.01, ***p < 0.001.A B
FIGURE 2 | HPV16-specific antibody responses measured by PsV-ELISA six years after the last dose of 4vHPV. (A) HPV-specific IgG levels (B) HPV-specific IgM
levels. Each dot represents an individual sample; error bars represent geometric mean ± 95% confidence interval. *p < 0.05, ***p < 0.001.October 2020 | Volume 11 | Article 585768
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using ELISA values from unvaccinated girls with negative PBNA
results (N=17, excluding one outlier), and was 0.374 EU/ml. Based
on this, the sensitivity and specificity for the PsV ELISA compared
to PBNA is 94.0% and 56.5%, respectively (Table 3).DISCUSSION
Using a PsV-based ELISA, we were able to differentiate IgG and IgM
antibodies from previously immunized and unimmunized girls. AsFrontiers in Immunology | www.frontiersin.org 6expected, we found that the majority of NAbs were IgG in previously
immunized girls, and that unimmunized girls receiving their first
dose of HPV vaccine have a combination of IgG and IgM antibodies,
one month following vaccination. Our results suggest that a PsV-
based ELISA may be used as an alternative to the PBNA, and VLP-
based ELISA for the measurement of HPV-specific antibody
responses following vaccination. The main benefit of this assay is
that the materials/reagents are easier to produce and/or are
commercially available. The advantage of this assay over VLP-
based ELISA is that the PsV does not require purification unlike
VLPs. Compared to PBNA, it is simpler and quicker to perform, andA B
C D
FIGURE 5 | Correlation of NAb titers (ED50) produced by PBNA with IgG levels (EU/ml) produced by PsV16-ELISA stratified by dosage groups. (A) 3-dose group
(B) 2-dose group (C) 1-dose group (D) 0-dose group. ED50: effective dose 50.A
A B
FIGURE 4 | Correlation of NAb titers (ED50) produced by PBNA with antibody levels produced by PsV16-ELISA. (A) IgG (B) IgM. ED50: effective dose 50.October 2020 | Volume 11 | Article 585768
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advantage of being able to measure antibody characteristics such as
isotype (IgG, IgM, IgA, and IgE) and subclasses (IgG1, IgG2, IgG3,
IgG4, IgA1, and IgA2), as well as antibody avidity. The clinical
relevance of these antibody characteristics is unknown, but they will
provide us with a better understanding of the antibody responses of
HPV vaccinated individuals, particularly in the context of a single
doseHPV vaccine schedule, where the antibody levels are lower. One
limitation of this assay is that it detects both neutralizing and non-
neutralizing antibodies, similar to most ELISAs, which can
sometimes over-estimate the antibody response. This is reflected
by the high sensitivity and moderate specificity analysis observed
when comparing this assay to PBNA. The moderate specificity of
this assay may be due neutralizing antibodies other than IgG, as wellFrontiers in Immunology | www.frontiersin.org 7as the presence of cross-reactive non-neutralizing antibodies
generated by infection with other HPV types. It is important to
note our negative control sera used to determine the seropositivity
cut-off were from Fijian girls in the 0-dose group who had no
detectable neutralizing antibody however we cannot rule out the
possibility that other antibodies may be present (e.g., non-
neutralizing). As such, our sample size was small and HPV
infection status was unknown. Nevertheless, this assay is unlikely
to significantly affect the analysis of the HPV IgG results, since the
IgG antibody levels detected using this assay strongly correlated with
the neutralizing antibody titers from PBNA, consistent with the
VLP-based ELISA (10, 11).
We have observed that some clinical samples have biological
interferences in the serological assays which do not dilute out with
one or two dilutions. Therefore, it is important to perform several
dilutions (three to four dilutions) of each sample, and in duplicate
wells at least, so that the data generated are more robust. Other
suggestions are standard good laboratory practices which includes
performing samples from the same individuals on the same plate
(e.g., pre- and post-samples) to eliminate inter-plate variations as
well as appropriate controls (i.e., pooled serum controls, as well as
serum with high and low antibody levels) to eliminate inter-plate
and inter-assay variations. In addition, it is also important to
validate new batches of PsV or produce sufficient quantity for a
complete study to eliminate any potential batch variation.
The current International Standards (IS) for HPV16 and 18 that
define the International Units (IU) of HPV antibodies can assist inTABLE 3 | Assay agreement between PsV-ELISA and PBNA.
HPV16 PsV-ELISA
PBNA Positive Negative Total
Positive 110 10 120
Negative 7 13 20




Positive predictive value (%) 91.6
Negative predictive value (%) 65.0A B
C D
FIGURE 6 | Correlation of NAb titers (ED50) produced by PBNA with IgM levels (EU/ml) produced by PsV16-ELISA stratified by dosage groups. (A) 3-dose group
(B) 2-dose group (C) 1-dose group (D) 0-dose group. ED50: effective dose 50.October 2020 | Volume 11 | Article 585768
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from the National Institute of Biological Standards and Controls
(NIBSC, Potters Bar, UK). These standards are produced from
individuals who generated antibodies to natural infection, where the
antibody levels are generally low (12). An IS with a more directly
comparable IU from vaccinated individuals and also to the
additional 5 oncogenic types included in Gardasil®9 will be more
representative for serological examination of the current vaccines.
Such an IS is currently being developed and undergoing validation
(6). This IS will be extremely useful in the global harmonization of
HPV serology testing in clinical trials of HPV prophylactic vaccines.
While antibodies are thought to be the primary mechanisms of
protection, memory B cells are also likely to be involved in
protection, and may be a better surrogate for long-term
protection. This is currently of great interest for reduced-dose
HPV vaccine schedules, particularly single dose schedules. B-cell
ELISPOT assays using HPVVLP antigens have been developed and
evaluated for the monitoring of HPV16/18 memory B-cell
responses in vaccinated women. In this case, the PsV antigens
could also be adapted for memory B cell ELISPOT assay, but
requires further evaluation.
In conclusion, we developed a rapid and simple PsV-based
ELISA to measure serumHPV antibodies. This assay can be used as
an alternative method to circumvent some of the limitations of the
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